Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Y-Mabs Therapeutics Inc (YMAB)

Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 752,422
  • Shares Outstanding, K 43,873
  • Annual Sales, $ 84,820 K
  • Annual Income, $ -21,430 K
  • 60-Month Beta 0.78
  • Price/Sales 8.92
  • Price/Cash Flow N/A
  • Price/Book 7.45
Trade YMAB with:

Options Overview Details

View History
  • Implied Volatility 88.38% ( -3.82%)
  • Historical Volatility 53.67%
  • IV Percentile 83%
  • IV Rank 25.77%
  • IV High 243.25% on 06/30/23
  • IV Low 34.61% on 11/14/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 18
  • Volume Avg (30-Day) 45
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 1,226
  • Open Int (30-Day) 1,200

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.12
  • Number of Estimates 3
  • High Estimate -0.11
  • Low Estimate -0.13
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.34 +28.56%
on 04/10/24
17.78 -3.53%
on 05/03/24
+2.73 (+18.93%)
since 04/03/24
3-Month
11.70 +46.58%
on 02/08/24
20.90 -17.94%
on 03/01/24
+3.15 (+22.50%)
since 02/02/24
52-Week
4.60 +272.83%
on 08/14/23
20.90 -17.94%
on 03/01/24
+11.01 (+179.32%)
since 05/03/23

Most Recent Stories

More News
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)

/PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) concerning possible breaches of...

YMAB : 17.15 (-0.58%)
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 51.61% and 29.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

YMAB : 17.15 (-0.58%)
SLDB : 10.10 (-1.27%)
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 16.67% and 3.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

MIRM : 25.84 (+0.94%)
YMAB : 17.15 (-0.58%)
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know

Y-mAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

YMAB : 17.15 (-0.58%)
BPMC : 107.19 (+0.18%)
Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade

The consensus price target hints at an 111.1% upside potential for Y-mAbs Therapeutics, Inc. (YMAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in...

YMAB : 17.15 (-0.58%)
Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains?

Y-mAbs Therapeutics, Inc. (YMAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near...

YMAB : 17.15 (-0.58%)
DNLI : 17.14 (+1.96%)
Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 106.82% and 50.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

YMAB : 17.15 (-0.58%)
EXAS : 62.07 (+2.53%)
Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

WVE : 6.14 (+4.42%)
YMAB : 17.15 (-0.58%)
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Y-mAbs Investors of a Lead Plaintiff Deadline of March 20, 2023

/PRNewswire/ -- Attention Y-mAbs Therapeutics, Inc. ("Y-mAbs") (NASDAQ: YMAB) shareholders: The Law Offices of Vincent Wong announce that a class action...

YMAB : 17.15 (-0.58%)
Y-MABS INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or...

YMAB : 17.15 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics...

See More

Key Turning Points

3rd Resistance Point 18.41
2nd Resistance Point 18.10
1st Resistance Point 17.62
Last Price 17.15
1st Support Level 16.83
2nd Support Level 16.51
3rd Support Level 16.04

See More

52-Week High 20.90
Last Price 17.15
Fibonacci 61.8% 14.67
Fibonacci 50% 12.75
Fibonacci 38.2% 10.83
52-Week Low 4.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar